Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab

Clinical and Translational Oncology

Volumn 9, Issue 2, 2007, Pages 119-120

  Gonzalez Cao M ^a   Viteri, S ^a   Garran C ^a   Nieto, Y ^a   Aristu, J ^a   Ponz, M ^a   Martin Algarra S ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Bevacizumab; Melanoma; Taxol

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CISPLATIN; DACARBAZINE; FOTEMUSTINE; INTERLEUKIN 2; PACLITAXEL; TAMOXIFEN; TEMOZOLOMIDE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RESISTANCE; CASE REPORT; CERVICAL LYMPHADENOPATHY; CLINICAL FEATURE; DISEASE FREE SURVIVAL; DRUG RESPONSE; DRUG TOLERANCE; ESOPHAGITIS; FEMALE; FOLLOW UP; HUMAN; LYMPHADENECTOMY; LYMPHADENOPATHY; MELANOMA; METASTASIS; RADIATION DOSE; REPEAT PROCEDURE; SUBCUTANEOUS NODULE; TREATMENT RESPONSE; DRUG ADMINISTRATION; DRUG RESISTANCE; REMISSION; SKIN TUMOR;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MELANOMA; PACLITAXEL; REMISSION INDUCTION; SKIN NEOPLASMS;

EID: 34347211811     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-007-0023-6     Document Type: Article

References (6)

1. Pawlak WZ, Legha SS (2004) Phase II study of thalidomide in patients with metastatic melanoma. Melanoma Res 14:57-62
2. Kabbinavar FF, Hambleton J, Mass RD et al (2005) Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23:3706-3712
3. Sandler AB, Gray R, Brahmer J et al (2005) Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. ASCO 2OO5, abst 4. J Clin Oncol 23[Suppl]:LBA4
4. Miller KD, Wang M, Gralow J et al (2005) A randomised phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 94[Suppl 1]:792-799
5. Legha SS, Ring S, Papadopoulos N et al (1990) A phase II trial of taxol in metastatic melanoma. Cancer 65:2478-2481
6. Campone M, Fumoleau P (2002) Weekly administration of paclitaxel in the treatment of metastatic breast cancer: From rational to practice. Bull Cancer 89:275-282